Your browser is old and is not supported. Upgrade for better security.

Invest in Corvidane

Developing a novel, safe drug to prevent heart attacks, strokes, and liver transplants from NASH

Highlights

1
CEO designed trials for Vascepa®, which reduces heart attack and stroke risk for high triglycerides.
2
Awarded $700k from Dutch government to perform more studies on our drug Corvida™'s potential.
3
Results of Corvida™'s affect on genes associated with atherosclerosis due in 2022.
4
Funds raised will lead to PreIND meetings with the FDA to ensure acceptability of human trials.
5
Corvida™'s components are designated GRAS (Generally Regarded as Safe) by the FDA.
6
Corvida™ is protected by patents in the US and Japan and are owned by the company.
7
This is an opportunity for you to impact global health and potentially realize significant financial gains.

Our Team


Pitch


Downloads

Overview